Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
Van Andel Research Institute, Grand Rapids, Michigan, USA.
Mov Disord. 2018 May;33(5):678-683. doi: 10.1002/mds.27383. Epub 2018 Mar 30.
Disease modification and structural neuroprotection have been the holy grail for Parkinson's disease (PD) experimental therapeutics. Theoretically, there are a number of ways to implement such therapeutics, but to date all have failed. This review examines the potential of axonal regeneration and trophic factor delivery for the nigrostriatal system as 2 such approaches that historically have initiated much excitement. However, we conclude this discussion with the following question: has science passed these approaches by? © 2018 International Parkinson and Movement Disorder Society.
疾病修饰和结构神经保护一直是帕金森病（PD）实验治疗的圣杯。从理论上讲，有许多方法可以实现这种治疗，但迄今为止，所有方法都失败了。这篇综述检查了轴突再生和神经营养因子输送到黑质纹状体系统的潜力，作为两种有希望的方法。然而，我们在讨论结束时提出了以下问题：科学是否已经超越了这些方法？ © 2018 国际帕金森病和运动障碍学会。
